1. Know where you are in the information flow - if you're buying because it's pumping, you're late 2. Accept that you will miss projects and selling early--most projects never regain post-launch/pre-reveal highs and when the music stops, you may be holding forever

So if @AnthropicAI can't secure as much compute as @OpenAI and @spacexai on compute, it would make sense to try to slow down the release of new models (via regulation, etc.) which eat into their coding moat, especially ahead of their IPO. It would also make sense for them to use Mythos 2, 3 internally to solve a high value problems in a specific industry like biology/medicine as @DarioAmodei has called out as optimistic AI examples for the good of humanity. Is this not the most bearish scenario for existing pharma/biotech who are dependent on drugs/therapies that would die if diseases were actually cured? Is this not the next industry to get the full software treatment as Ant would have superior models, engineering, and incentives and this would be much more valuable than whatever data from past trials pharma companies might have? Where am I wrong @grok This would be a hugely positive scenario imo, I'm okay using other models to write code and do my knowledge work.

This #KarenRead trial is the dystopian version of the Truman Show. I mean nobody in that courtroom can really believe that she did this at this point and yet they’re still going to keep throwing things at the wall.

These Magic lineup choices are terrible…If all of our guards belong in the D-League, then just play Isaac. Cory Joseph and Caleb Houston shouldn’t be seeing the floor in the playoffs. After all the cap space we had this summer, this is negligence.